The last patient has completed their final visit.
In the long and often humbling search for treatments that address the roots of Parkinson's disease rather than merely its symptoms, a small biotech company named BioVie has reached a quiet but consequential threshold: the last patient in its bezisterim trial has completed their final visit. The company now enters the unglamorous interlude between clinical action and clinical knowledge — processing data, awaiting biomarker results, and preparing for a readout expected sometime between late spring and early autumn of 2026. What emerges from that analysis will not only determine the fate of a drug candidate, but will test whether a novel mechanism of action can translate the language of biology into genuine relief for those living with neurodegeneration.
- BioVie's Parkinson's trial has crossed its enrollment finish line, but the most consequential work — data reconciliation and biomarker analysis — is only now beginning.
- Biomarker results are the linchpin: they will reveal whether bezisterim is doing what the company believes it does at a biological level, not just a symptomatic one.
- A potential slip from Q2 into Q3 2026 carries real weight — in biotech, a few months can determine whether a company attracts partners, secures financing, or loses momentum entirely.
- BioVie is running a second parallel trial, quietly hedging its risk while keeping the Parkinson's program as its flagship and primary proof of concept.
- The company and its investors now occupy the familiar, suspended tension of biotech's waiting room — certain that an answer is coming, uncertain what it will say.
On May 7, BioVie Inc. convened a virtual event to update investors and clinicians on its two active clinical programs, with CEO Cuong Do centering his remarks on bezisterim, the company's Parkinson's disease drug candidate. The headline was straightforward: the trial has reached its enrollment endpoint, and the last patient has completed their final visit.
What follows that milestone is less visible but no less important. BioVie's team is now deep in study closeout — reviewing data points, reconciling inconsistencies, and preparing the full dataset for analysis. The company is also awaiting biomarker results, which will reveal not just whether the drug appears to work, but whether it is working through the specific biological mechanisms the company has staked its thesis on. Do indicated the team hopes to complete the full analysis by end of Q2 2026, while acknowledging a possible slide into Q3 depending on how quickly the biomarker data arrives and can be processed.
The timing carries outsized significance. For a company operating in the early-stage biotech space — where cash burn is constant and proof points are existential — the difference between a June readout and a September one can reshape financing conversations, partnership interest, and investor confidence. Bezisterim represents a deliberate bet that Parkinson's disease can be addressed at the level of underlying pathology rather than symptom management alone, targeting the biological processes that drive neurodegeneration.
BioVie is also running a second trial in a separate indication, suggesting a measured effort to diversify risk. But the Parkinson's program remains the company's flagship. By summer or early fall, the data will answer the question that defines BioVie's near-term future: whether bezisterim is a genuine therapeutic candidate, or an intriguing mechanism that stops short of human benefit.
BioVie Inc. held a virtual event on May 7 to walk investors and clinicians through the status of its two active clinical trials, with particular focus on bezisterim, a drug candidate being tested in Parkinson's disease. The company's chief executive, Cuong Do, delivered the update: the Parkinson's trial has reached its enrollment endpoint. The last patient has completed their final visit. Now the real work begins—the unglamorous, essential work of closing out a study.
What happens after the last patient walks out of the clinic is invisible to most observers but critical to the timeline. BioVie's team is moving through the study closeout process, which means reviewing every data point, checking for errors, reconciling inconsistencies, and preparing the dataset for analysis. It's methodical work. It's also where delays often hide.
The company is waiting on biomarker data—measurements that reveal what the drug is actually doing inside the body at a biological level. These aren't just efficacy numbers; they're the mechanistic proof that bezisterim is working the way the company believes it works. Do said the team is aiming to have all data in hand and fully analyzed by the end of the second quarter of 2026, though he acknowledged the possibility of slippage into the third quarter depending on how quickly the biomarker results arrive and can be processed.
The timing matters enormously. In the biotech world, a completed trial dataset is currency. It determines whether a company can move toward regulatory discussions, whether it can attract partnership interest, whether it can justify its valuation. For a company like BioVie, which exists in the preclinical-to-early-stage space where cash burn is relentless and proof points are everything, the difference between June and September can reshape the entire trajectory.
Bezisterim itself represents a particular bet: that there is a novel mechanism of action worth pursuing in Parkinson's disease, a condition where existing treatments address symptoms but not underlying pathology. The drug is designed to target specific disease mechanisms—the biological processes that drive neurodegeneration. Whether it actually does this, and whether doing so translates to clinical benefit for patients, is what the trial data will reveal.
The company is running two trials in parallel, though Do's remarks focused primarily on the Parkinson's program. The existence of a second trial suggests BioVie is hedging its bets, testing bezisterim in another indication to diversify its risk. But the Parkinson's trial is clearly the flagship—the one that will determine whether the company has a genuine therapeutic candidate or an interesting mechanism that doesn't translate to human benefit.
For now, BioVie is in the waiting room. The patients have been seen. The data is being collected and cleaned. The biomarkers are being measured. By summer or early fall, the company will know whether it has something worth taking forward. That knowledge will reshape everything that comes next—the regulatory path, the financing strategy, the partnership conversations, the stock price. Until then, the company and its investors are in the familiar biotech position of knowing something is coming but not knowing what it will say.
Citações Notáveis
The last patient has come in for his last visit. Our team is working through the study closeout process right now to go through all the data and clean it up.— Cuong Do, CEO of BioVie
We are hoping to have everything in and analyzed by the end of this quarter, but it may slip into next quarter depending on how long it takes for us to get the biomarker data back.— Cuong Do, CEO of BioVie
A Conversa do Hearth Outra perspectiva sobre a história
Why does the biomarker data matter so much? Couldn't they just look at whether patients got better?
Biomarkers tell you the mechanism—whether the drug is actually doing what you designed it to do. A patient might feel better for lots of reasons. The biomarker proves the drug is hitting the target.
So if the biomarkers are good but patients didn't improve, that's actually useful information?
Exactly. It means the mechanism is sound but maybe the dose was wrong, or the patient population wasn't right, or the timeframe was too short. You can iterate. If the biomarkers are bad, you know the whole approach is flawed.
How long does it usually take to get biomarker data back?
It depends on what you're measuring and where the samples are being processed. Could be weeks, could be months. That's why Cuong was hedging—he doesn't control that timeline.
What happens if the data slips into Q3?
Investors get nervous. The company burns more cash waiting. But honestly, a few months doesn't change the fundamental question: does the drug work or not?
Is there a world where this trial fails but the company survives?
Sure. If the biomarkers look good but efficacy is marginal, they might partner with a larger company. Or they pivot to a different indication. But a complete failure? That's much harder to recover from.
Why run two trials at once if cash is tight?
Diversification. If one fails, you still have another shot. And if both work, you've got two shots at revenue. It's expensive, but the alternative is betting everything on one trial.